Literature DB >> 1550395

Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients.

R Cervera1, J Font, C Paré, M Azqueta, F Pérez-Villa, A López-Soto, M Ingelmo.   

Abstract

A prospective two dimensional and Doppler echocardiographic study of 70 consecutive patients with systemic lupus erythematosus (SLE) and 40 controls was carried out. Forty patients (57%) were found to have echocardiographic disturbance. Valvular abnormalities were detected in 31 patients (44%) and in only two controls (5%). Mitral valve abnormalities were the most common findings (23/70 (33%)) with mild or moderate regurgitation the most frequent lesion (16% and 9% respectively). Three patients (4%) had a morphological echocardiographic pattern suggestive of non-infective verrucous vegetations affecting the mitral valve. No patient had haemodynamically significant clinical valve disease. Pericardial effusion was identified in 19 patients (27%), of whom 14 had mild and clinically silent disease. Myocardial abnormalities were found in 14 patients (20%), but clinical features of myocardial dysfunction were present in only one. Patients with antiphospholipid antibodies were found to have an increased prevalence of endocardial lesions, mainly valvular regurgitation. It is concluded that the inclusion of echocardiography in a study protocol of patients with SLE can identify an important subset of patients with cardiac abnormalities, many of which are clinically silent. In addition, the association of antiphospholipid antibodies with endocardial lesions suggests that these antibodies may have a prominent role in the pathogenetic mechanisms of heart valve disease in SLE.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550395      PMCID: PMC1005649          DOI: 10.1136/ard.51.2.156

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.

Authors:  R Cervera; J Font; A López-Soto; F Casals; L Pallarés; A Bové; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

2.  Echocardiographic findings in systemic lupus erythematosus.

Authors:  N E Doherty; G Feldman; G Maurer; R J Siegel
Journal:  Am J Cardiol       Date:  1988-05-01       Impact factor: 2.778

3.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

4.  False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion.

Authors:  S Cowchock; J Fort; S Munoz; R Norberg; W Maddrey
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

5.  The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients.

Authors:  B H Bulkley; W C Roberts
Journal:  Am J Med       Date:  1975-02       Impact factor: 4.965

6.  Clinically significant valvular heart disease in systemic lupus erythematosus.

Authors:  K V Straaton; W W Chatham; J D Reveille; W J Koopman; S H Smith
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

7.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

8.  Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus.

Authors:  P M Ford; S E Ford; D P Lillicrap
Journal:  J Rheumatol       Date:  1988-04       Impact factor: 4.666

9.  Immunopathogenesis of Libman-Sacks endocarditis. Assessment by light and immunofluorescent microscopy in two patients.

Authors:  R F Shapiro; C N Gamble; K B Wiesner; J J Castles; A W Wolf; E J Hurley; A F Salel
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

10.  M-mode and two-dimensional echocardiographic abnormalities in systemic lupus erythematosus.

Authors:  A V Klinkhoff; C R Thompson; G D Reid; C W Tomlinson
Journal:  JAMA       Date:  1985-06-14       Impact factor: 56.272

View more
  23 in total

Review 1.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

2.  Hypertrophic cardiomyopathy and systemic lupus erythematosus.

Authors:  J Ara; J Vivancos; J Soler-Carrillo; J C Paré; R Cervera; J Font
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies.

Authors:  O Meyer; M Golstein; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 4.  Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review.

Authors:  Priscila Mattos; Mittermayer B Santiago
Journal:  Clin Rheumatol       Date:  2011-01-05       Impact factor: 2.980

5.  Ambulatory blood pressure and subclinical cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus.

Authors:  Nur Canpolat; Ozgur Kasapcopur; Salim Caliskan; Selman Gokalp; Meltem Bor; Mehmet Tasdemir; Lale Sever; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2012-10-10       Impact factor: 3.714

Review 6.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

7.  Cardiac operations for North American children with rheumatic diseases: 1985-2005.

Authors:  Cory Stingl; James H Moller; Bryce A Binstadt
Journal:  Pediatr Cardiol       Date:  2009-12-05       Impact factor: 1.655

8.  Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies.

Authors:  Piotr Leszczyński; Ewa Straburzyńska-Migaj; Izabela Korczowska; Jan K Łacki; Stefan Mackiewicz
Journal:  Clin Rheumatol       Date:  2003-10-14       Impact factor: 2.980

Review 9.  Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis.

Authors:  Junzhe Chen; Ying Tang; Mingsheng Zhu; Anping Xu
Journal:  Clin Rheumatol       Date:  2016-08-09       Impact factor: 2.980

10.  Systemic lupus erythematosus presenting as effuso-constrictive pericarditis.

Authors:  S R McMechan; B M McClements; P P McKeown; S W Webb; A A Adgey
Journal:  Postgrad Med J       Date:  1995-10       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.